Contract Research & Clinical Trials in India: CDSCO, Ethics Committee & FDI

Why India Is Emerging as a Global Clinical Trials Hub

India's clinical research landscape has transformed significantly since the introduction of the New Drugs and Clinical Trials Rules (NDCTR) in 2019. With over 1,000 clinical trials reported in 2025 alone and the Indian CRO market projected to grow at a CAGR exceeding 11%, foreign pharmaceutical companies and Contract Research Organizations (CROs) are increasingly choosing India for their clinical programs.

The advantages are compelling: India offers a genetically diverse population of 1.4 billion across varied ethnic groups, a large treatment-naive patient pool, English-speaking investigators, lower operational costs (40-60% savings compared to the US and Europe), and a regulatory framework that has been steadily aligning with international standards. Global pharmaceutical companies including Pfizer, Novartis, and AstraZeneca have established significant clinical research operations in India.

For foreign companies considering clinical research operations in India, understanding the regulatory framework—particularly the roles of CDSCO, the Drugs Controller General of India (DCGI), and Institutional Ethics Committees (IECs)—is essential. Equally important is structuring the investment under India's FDI policy to ensure compliance with FEMA and sectoral regulations.

FDI Policy for Pharmaceutical and CRO Operations

India's FDI policy for the pharmaceutical sector is structured as follows:

Greenfield Pharmaceutical Projects

100% FDI is permitted under the automatic route for greenfield pharmaceutical undertakings. This includes setting up new CRO operations, clinical research facilities, or pharmaceutical R&D centres from scratch. No prior government approval is required—the investor simply incorporates an Indian entity, brings in capital, and commences operations.

Brownfield Pharmaceutical Projects

For acquiring or investing in existing pharmaceutical companies or CROs:

• Up to 74% FDI: Automatic route (no government approval needed)
• Beyond 74% up to 100%: Government approval required from DPIIT

The brownfield policy includes important safeguards: the government may impose conditions requiring the investee company to maintain a certain level of domestic production of essential medicines and R&D spending. Non-compete clauses that restrict Indian promoters from continuing in the same business line are prohibited.

Contract Research Organizations (CROs)

CROs providing clinical trial management services fall under the pharmaceutical services category. A foreign CRO setting up a new Indian entity qualifies as greenfield (100% automatic route). Acquiring an existing Indian CRO follows the brownfield route (74% automatic, beyond 74% with government approval).

Practical Structuring

Most foreign pharma companies and CROs entering India set up a wholly-owned subsidiary as a Private Limited Company. The subsidiary can then:

• Apply for CDSCO registrations and licenses
• Enter into clinical trial agreements with Indian hospitals and investigators
• Employ clinical research professionals directly
• Own or lease laboratory and office facilities
• Import investigational drugs under a CDSCO-issued license

CDSCO: The Central Regulatory Authority

The Central Drugs Standard Control Organisation (CDSCO) is India's apex drug regulatory body, operating under the Ministry of Health and Family Welfare. It is headed by the Drugs Controller General of India (DCGI), who is designated as the Central Licensing Authority (CLA) under the NDCTR, 2019.

CDSCO's Role in Clinical Trials

CDSCO is responsible for:

• Reviewing and approving Clinical Trial Applications (CTAs)
• Registering Ethics Committees
• Registering CROs (mandatory from April 1, 2025)
• Monitoring ongoing trials through safety reporting
• Inspecting clinical trial sites
• Granting import licenses for investigational new drugs

CDSCO Approval Timelines

The "deemed approval" provision—where permission is automatically granted if CDSCO does not respond within the prescribed timeline—was a landmark change under NDCTR 2019, providing regulatory certainty that was previously lacking.

New Drugs and Clinical Trials Rules (NDCTR), 2019

The NDCTR, 2019 replaced the outdated provisions of Schedule Y of the Drugs and Cosmetics Rules, 1945, establishing a modern, comprehensive regulatory framework. Key features relevant to foreign companies include:

Scope of NDCTR

The rules regulate:

• New drugs: Entirely new pharmaceutical products not previously approved in India
• Investigational new drugs (IND): Unapproved drugs studied for safety and efficacy
• Subsequent new drugs (SND): New forms, strengths, or combinations of already approved drugs
• Fixed-dose combinations (FDCs)
• Clinical trials, bioavailability, and bioequivalence studies

Clinical Trial Phases in India

For drugs discovered outside India, the sponsor can submit Phase I data from overseas along with the Indian CTA. However, Phase III trials must be conducted in India with Indian subjects before the drug can receive marketing authorization.

Global Clinical Trials in India

India participates actively in global multicentre clinical trials (GCTs). For a GCT, the foreign sponsor must:

• File a CTA with CDSCO providing global trial protocol, investigator brochure, and overseas Phase I data
• Obtain CDSCO approval within 90 working days
• Obtain approval from each participating site's Ethics Committee
• Appoint an Indian medical expert as the local principal investigator
• Ensure insurance/compensation coverage for trial subjects per Rule 39 of NDCTR

CRO Registration Requirement (Effective April 2025)

From April 1, 2025, all CROs must be registered with the Central Licensing Authority before conducting clinical trials or BA/BE studies involving new or investigational drugs in humans. This registration requirement applies to both Indian and foreign-owned CROs operating in India. The registration involves submission of organizational details, quality systems documentation, and details of qualified personnel.

Ethics Committee Framework

Ethics Committees (officially termed Institutional Ethics Committees, or IECs) provide the ethical oversight for all clinical trials conducted in India. No trial can begin at a site without prior approval from that site's registered Ethics Committee.

Ethics Committee Registration

• Registration with CDSCO is mandatory for all Ethics Committees
• Registration is valid for 3 years (5 years under NDCTR 2019) and must be renewed before expiry
• Re-registration applications must be filed at least 3 months before expiry
• Only CDSCO-registered Ethics Committees can approve clinical trials

Ethics Committee Composition

Under NDCTR 2019, an Ethics Committee must include:

• A medical scientist (chairperson, from outside the institution)
• At least one lay person
• At least one legal expert
• At least one social scientist or representative of a non-governmental organization
• At least one member with relevant scientific expertise
• The committee must have members of both genders

Ethics Committee Review Process

The Ethics Committee reviews:

• Scientific merit and design of the trial
• Risk-benefit assessment for participants
• Informed consent documents (must be in the local language)
• Investigator qualifications and site facilities
• Insurance and compensation provisions for subjects
• Data safety monitoring plan

The Ethics Committee must notify CDSCO within 15 working days of granting approval for a clinical trial. This creates a dual-oversight mechanism where both CDSCO and the Ethics Committee must independently approve the trial.

Site Selection and Investigator Requirements

Choosing the right clinical trial sites in India is a critical success factor. India has over 3,500 hospitals and clinical research centres, but not all meet the standards required for international clinical trials.

Key Site Selection Criteria

• Accreditation: NABH-accredited hospitals (National Accreditation Board for Hospitals) provide a baseline quality assurance. For oncology trials, accreditation from NABL (National Accreditation Board for Testing and Calibration Laboratories) for the hospital's diagnostic laboratory is essential.
• Patient volume: The site must demonstrate adequate patient footfall in the relevant therapeutic area. India's strength lies in high volumes for cardiology, oncology, diabetes, respiratory diseases, and infectious diseases.
• Infrastructure: Emergency resuscitation facilities, dedicated clinical trial pharmacy with temperature-controlled storage, investigational product management systems, and electronic data capture (EDC) capability.
• Investigator qualifications: The principal investigator must hold a medical qualification recognized by the Medical Council of India (now National Medical Commission), have appropriate specialization, and ideally have prior clinical trial experience with GCP training certification.

Top Clinical Trial Hubs in India

Investigator Agreements

The sponsor or CRO must enter into a Clinical Trial Agreement (CTA) with each site institution and principal investigator. Key terms to negotiate include: investigator fees (typically INR 15,000 to INR 50,000 per evaluable patient depending on the therapeutic area and trial complexity), pharmacy fees, laboratory charges, Ethics Committee review fees, and institutional overhead charges. All payments to investigators must be at arm's-length rates and properly documented for transfer pricing purposes if the paying entity is a foreign-owned Indian subsidiary.

Compensation and Insurance Requirements

India has among the most robust subject protection frameworks globally. NDCTR 2019 specifies detailed compensation requirements:

Compensation for Trial-Related Injury

• The sponsor must provide free medical management for any trial-related injury for as long as required
• Financial compensation must be paid for trial-related injuries, including serious adverse events
• In case of death during a clinical trial, the cause must be determined and compensation paid if the death is related to the trial
• The amount of compensation is determined based on a formula prescribed in NDCTR (Rule 39 and Schedule VII)

Insurance

The sponsor must maintain insurance coverage for clinical trial subjects. The insurance must cover:

• Medical treatment costs for trial-related injuries
• Compensation for disability or death
• Coverage must continue for at least one year after the last subject's last visit

Setting Up Clinical Trial Operations: Step-by-Step

1. Incorporate Indian entity: Set up a wholly-owned subsidiary or JV as a Private Limited Company via SPICe+. Appoint at least one resident director. Obtain PAN, TAN, GST registration, and other business registrations.
2. Capital infusion: Wire investment capital through banking channels. File FC-GPR with the AD bank within 30 days of share allotment. For greenfield pharma operations, 100% FDI is permitted under the automatic route.
3. CRO registration (if applicable): Register the CRO with CDSCO's Central Licensing Authority. Provide organizational details, quality management systems, and personnel qualifications.
4. Identify trial sites: Select hospitals and clinical research centres with CDSCO-registered Ethics Committees, adequate patient population, qualified investigators, and necessary infrastructure (pharmacy, laboratory, emergency facilities).
5. File Clinical Trial Application: Submit CTA to CDSCO through the SUGAM online portal. Include trial protocol, investigator brochure, informed consent documents, regulatory history in other countries, and overseas trial data (if applicable).
6. Ethics Committee approval: Submit the protocol to each site's Ethics Committee for independent review. The Ethics Committee must notify CDSCO within 15 working days of granting approval.
7. Import investigational drug: Obtain an import license from CDSCO for the investigational product. The drug must be shipped through authorized ports with proper customs documentation.
8. Initiate trial: After both CDSCO and Ethics Committee approvals, recruit subjects, conduct the trial per GCP guidelines, and file periodic safety reports with CDSCO.
9. Ongoing compliance: File FLA returns annually by July 15. Maintain FEMA/RBI compliance for all cross-border payments including investigator payments, site fees, and vendor payments.

Tax Considerations for Foreign CROs and Pharma Companies

Corporate Tax

The Indian subsidiary pays corporate tax at ~25.17% under Section 115BAA (if it forgoes exemptions) or the standard ~34.94% rate. New manufacturing companies can opt for the 15% rate under Section 115BAB (window for new manufacturing companies closed on 31 March 2024), but this applies only to manufacturing, not services like CRO operations.

R&D Tax Incentives

Expenditure on in-house R&D approved by the Department of Scientific and Industrial Research (DSIR) is eligible for weighted deduction under Section 35(2AB) of the Income Tax Act. This can significantly reduce the effective tax rate for companies conducting genuine R&D in India.

Transfer Pricing

Cross-border payments between the foreign parent and Indian subsidiary—including service fees, technology licensing, cost-sharing arrangements, and management fees—must comply with transfer pricing regulations. The arm's-length principle applies, and transfer pricing documentation must be maintained.

Withholding Tax on Cross-Border Payments

Payments to foreign investigators, overseas CROs, or technology providers are subject to withholding tax under Section 195 of the Income Tax Act. The applicable rate depends on the nature of payment and the relevant DTAA. A Form 15CA/15CB certificate is required for all outward remittances.

Import and Customs for Investigational Products

Importing investigational drugs into India requires a specific process that foreign sponsors must navigate carefully:

Import License for Clinical Trial Drugs

CDSCO issues a separate import license for investigational products. The application must include the drug's composition, manufacturing details, Certificate of Analysis (CoA), Good Manufacturing Practice (GMP) certificate of the manufacturing facility, and the approved clinical trial protocol. The import license specifies the quantity permitted, which must align with the number of subjects in the approved trial protocol.

Customs Clearance

Investigational drugs are typically exempt from customs duty under Notification No. 12/2012-Customs (as amended) when imported for approved clinical trial purposes. However, the importer must present the CDSCO import license, trial approval letter, and a declaration that the drugs are solely for clinical trial use. Drugs must be imported through designated ports with the required cold-chain infrastructure if temperature-sensitive. Mumbai, Delhi, Chennai, and Hyderabad are the primary ports of entry for clinical trial materials.

Drug Accountability and Destruction

The sponsor must maintain complete drug accountability records—tracking every unit of investigational product from import to dispensing to return or destruction. Unused investigational products must be destroyed in the presence of authorized witnesses, with destruction certificates maintained as part of the trial master file. This documentation is reviewed during CDSCO inspections and GCP audits.

Data Protection and Intellectual Property

Clinical Trial Data Protection

India's Digital Personal Data Protection Act, 2023 (DPDPA) applies to clinical trial data containing personal information. Key requirements include:

• Consent from data principals (trial subjects) for processing personal data
• Data localization requirements for certain categories of sensitive data
• Cross-border data transfer is permitted to notified countries, with restrictions on others
• Data fiduciary (the sponsor/CRO) must implement reasonable security safeguards

Patent Protection

India's patent regime under the Patents Act, 1970 (as amended) provides 20-year patent protection. However, Section 3(d) of the Act restricts patents on incremental innovations (new forms of known substances) unless significantly enhanced efficacy is demonstrated. Foreign pharma companies must factor this into their IP strategy for drugs being trialed in India.

Key Therapeutic Areas and India's Competitive Advantage

India's clinical trial strengths vary by therapeutic area. Foreign sponsors should align their trial portfolios with India's natural advantages:

Oncology

India has a high incidence of head and neck cancers, cervical cancer, and oral cancers that are rarer in Western populations, making it an ideal location for trials targeting these conditions. Major cancer centres like Tata Memorial Hospital (Mumbai), AIIMS (Delhi), and Adyar Cancer Institute (Chennai) have extensive clinical trial capabilities and experienced investigators.

Cardiovascular and Metabolic Diseases

India has the world's largest diabetic population (over 100 million adults) and a high burden of cardiovascular disease, often presenting at younger ages compared to Western populations. This provides rapid patient recruitment for trials in diabetes, hypertension, dyslipidemia, and heart failure. The ICMR (Indian Council of Medical Research) actively supports cardiovascular research.

Infectious Diseases

India's tropical climate and diverse infectious disease burden make it a natural hub for trials in tuberculosis, malaria, dengue, and hepatitis. The country's contribution to HIV/AIDS clinical research has been globally significant, and its TB research capabilities are particularly strong given India accounts for approximately 27% of the global TB burden.

Rare Diseases and Orphan Drugs

India's large population means that even rare diseases have significant patient populations in absolute numbers. The government has introduced a National Policy for Rare Diseases (2021) with provisions for supporting clinical trials in rare diseases, including orphan drug development pathways.

Recent Regulatory Developments (2025-2026)

CRO Registration Mandate (April 2025)

The mandatory CRO registration requirement effective April 1, 2025, adds regulatory oversight but also provides legitimacy and quality assurance. Foreign CROs should register promptly to avoid operational disruptions.

NDCTR Amendment (March 2026)

The New Drugs and Clinical Trials (Amendment) Rules, 2026, effective March 7, 2026, replaced the approval requirement for certain low-risk Bioavailability/Bioequivalence (BA/BE) studies with a prior-intimation mechanism. This significantly reduces timelines for generic drug development studies.

Market Growth

India's clinical trials market is projected to grow at a CAGR of 8-12% through 2030, driven by the country's cost advantages, regulatory improvements, and increasing global pharma companies outsourcing R&D to India. The Indian preclinical CRO market alone is estimated at USD 220 million in 2025, expected to reach USD 301 million by 2030.

Key Takeaways

• 100% FDI is permitted under the automatic route for greenfield pharma and CRO operations in India—no government approval required
• CDSCO approval timelines are 30 working days for India-developed drugs and 90 working days for global trials, with deemed approval if no response is received
• CRO registration with CDSCO is mandatory from April 2025 for all entities conducting clinical trials
• Ethics Committee approval is required independently at each trial site, with CDSCO notification within 15 working days
• India's subject protection framework is among the most robust globally, requiring insurance, compensation for trial-related injuries, and detailed informed consent
• Engage FDI advisory and FEMA compliance specialists early to structure the Indian entity, capital infusion, and ongoing regulatory compliance correctly